ArticleBrain imaging and behavior2026
Brain network dysfunction and treatment-induced network reorganization in major depressive disorder.
Article in Brain imaging and behavior, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The present study aimed to investigate the characteristics of abnormal resting-state brain-network connectivity and the reorganization effects of antidepressant drug escitalopram oxalate treatment in patients with major depressive disorder (MDD), and to explore spatial correlations between brain network alterations and gene expression profiles. We employed a longitudinal study design to recruit 113 patients with MDD and 114 healthy controls (HCs) between November 2020 and October 2022. Clinical symptoms were assessed using the 17-item Hamilton Depression Scale (HAMD-17). Resting-state functional magnetic resonance imaging (rs-fMRI) data were acquired using a Siemens 3.0 T MRI scanner. At baseline, patients with MDD exhibited significantly reduced functional connectivity (FC) within the default mode network (DMN) compared to HCs, along with significantly increased FC between the sensorimotor network (SMN) and both the frontoparietal network (FPN) and the salience network (SN) (False Discovery Rate, FDR-corrected, p < 0.05). Following treatment with escitalopram oxalate, MDD patients showed a significant enhancement in intra-DMN connectivity, as well as a significant reduction in SMN-FPN and SMN-SN connectivity (FDR-corrected, p < 0.05). Notably, the degree of increase in intra-DMN connectivity was significantly and negatively correlated with improvement in core depressive symptoms (r = - 0.305, p = 0.026), while the reduction in SMN-DMN connectivity was positively correlated with the alleviation of somatic symptoms (r = 0.362, p = 0.008). Further neuroimaging-guided transcriptomics analysis indicated that these alterations in brain network connectivity were linked to biological pathways, such as the Wnt signaling. In conclusion, our findings demonstrate a multidimensional imbalance in brain network connectivity in MDD and show that antidepressant treatment can partially ameliorate aberrant connectivity patterns. These neural changes are closely associated with symptomatic improvements, offering valuable imaging-based evidence for understanding the neurobiological mechanisms of MDD and informing the development of personalized treatment strategies.
Indexed as
Identifiers
41653205What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.